Auxilium Pharmaceuticals, Inc. (AUXL) Posts Q2 Loss of 44c/Share; Updates FY14 Outlook

Go back to Auxilium Pharmaceuticals, Inc. (AUXL) Posts Q2 Loss of 44c/Share; Updates FY14 Outlook

Auxilium (AUXL) Valuation Remains Attractive Following Q2 Results; Aegis Lowers PT to $34

August 7, 2014 10:13 AM EDT

Aegis Capital cuts its price target on Auxilium Pharmaceuticals (Nasdaq: AUXL) from $37 to $34 and affirms its Buy rating following Q2 results issued... More